Market capitalization | $411.73m |
Enterprise Value | $371.83m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.90 |
P/S ratio (TTM) P/S ratio | 2.10 |
P/B ratio (TTM) P/B ratio | 3.25 |
Sales growth (TTM) Sales growth | 26.48% |
Turnover (TTM) Turnover | $196.03m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
7 Analysts have issued a Treace Medical Concepts Inc forecast:
7 Analysts have issued a Treace Medical Concepts Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 196 196 |
26%
26%
|
|
Gross income | 159 159 |
27%
27%
|
|
EBITDA | -50 -50 |
42%
42%
|
EBIT (operating result) EBIT | -57 -57 |
40%
40%
|
Net profit | -55 -55 |
16%
16%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
Head office | United States |
CEO | John Treace |
Employees | 516 |
Founded | 2013 |
Website | www.treace.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.